Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Largest Population-Based Observational Study to Evaluate Pregnancy Outcomes in Women with Multiple Sclerosis (MS) Treated with Interferon Beta (IFN beta), Including Rebif (Interferon beta-1a) Before and During First Trimester

Next Previous
Trial Profile

A Largest Population-Based Observational Study to Evaluate Pregnancy Outcomes in Women with Multiple Sclerosis (MS) Treated with Interferon Beta (IFN beta), Including Rebif (Interferon beta-1a) Before and During First Trimester

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta (Primary) ; Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions

Most Recent Events

  • 11 Sep 2019 According to a Merck (DARMSTADT, Germany) media release, the reviews of safety data, from these interferon registries submitted with different health authorities, are currently ongoing.
  • 11 Sep 2019 New data on pregnancy outcomes at birth after exposure to interferon beta (IFN B), including Rebif (sc/subcutaneous interferon beta-1a) were presented in a Merck (DARMSTADT, Germany) media release.
  • 28 Aug 2019 According to an Merck & Co Media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top